Hardman Johnston Trims Illumina Stake

Institutional investor reduces position in life sciences company by 19.2% in Q4 2025.

Apr. 13, 2026 at 10:34am

Got story updates? Submit your updates here. ›

An extreme close-up of highly detailed, metallic mechanical components and gears, representing the complex inner workings of a life sciences technology company like Illumina. The image has a heavy, industrial feel, conveying a sense of power, precision, and technological prowess.An institutional investor's reduced stake in Illumina highlights broader shifts in market sentiment towards the life sciences industry.San Diego Today

Hardman Johnston Global Advisors LLC, an institutional investor, reduced its position in Illumina, Inc. (NASDAQ:ILMN) by 19.2% during the fourth quarter of 2025, according to a recent SEC filing. The firm now owns approximately 127,236 shares of the life sciences company's stock, valued at $16.7 million.

Why it matters

Illumina is a leading provider of DNA sequencing systems and related products, playing a crucial role in the life sciences and genomics industries. Changes in institutional ownership of Illumina shares can signal shifts in market sentiment and investor confidence in the company's performance and future prospects.

The details

Hardman Johnston Global Advisors sold 30,148 Illumina shares during the fourth quarter, reducing its total position to 127,236 shares. The firm now owns approximately 0.08% of Illumina's outstanding shares. Other large investors have also recently adjusted their stakes in the company, with some adding to their positions and others, like Hardman Johnston, reducing their exposure.

  • Hardman Johnston Global Advisors filed its Q4 2025 Form 13F with the SEC on April 13, 2026.
  • The firm's position change occurred during the fourth quarter of 2025.

The players

Hardman Johnston Global Advisors LLC

An institutional investment management firm that owns shares in Illumina, Inc.

Illumina, Inc.

A global life sciences company that develops, manufactures, and markets integrated systems for the analysis of genetic variation and function.

Got photos? Submit your photos here. ›

The takeaway

The reduction in Hardman Johnston's Illumina stake reflects broader market shifts and changes in investor sentiment towards the life sciences sector. However, Illumina remains a dominant player in the genomics industry, and its long-term prospects continue to be closely watched by institutional investors.